ProKidney Corp. - Class A Ordinary Shares — Quarterly Financial Statistics (NASDAQ:PROK) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -29.59 M-31.42 M-26.6 M-32.51 M-41.68 M -132.21 M Cash from investing activities 28.29 M18.57 M29.02 M28.09 M34.83 M 110.5 M Cash from financing activities -12 K-14 K7.96 M17.63 M215 K 25.8 M Free cash flow -29.59 M-31.42 M-26.6 M-32.51 M-41.68 M -132.21 M

News

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates

Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK)

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:PROK) 2026-01-14

H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target

This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Compass Minerals Intl (NYSE:CMP), MYR Group (NASDAQ:MYRG)

ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy

ProKidney Corp. (PROK) Presents at Morgan Stanley 23rd Annual